✅ پروژه ۵ میلیون پوندی جدید برای گسترش اقتصاد زیستی در شهر Yorkshire، منطقه Humber و Tees Valley در شمال انگلستان. ?پروژه THYME که یک کار ابتکاری ۳ ساله است، توسط دانشگاه York هدایت می‌شود. اهدافی که در این پروژه دنبال شده‌اند تکیه بر تجربه‌های پیشین، نوآوری و استفاده بهینه از مهارت متخصصان است که البته ارتباط این عوامل نیز …

Unity Biotechnology Finalizes $85 Million IPO Terms Summary Unity Biotechnology has filed proposed terms for its U.S. IPO. The firm is developing technologies to remove senescent cells from certain disease indications. UBX’s approach is differentiated and promising, but the company is still at pre-clinical stage Quick Take Unity Biotechnology (UBX) intends to sell $85 million in common stock for its U.S. …

✅امروزه در تجارت موضوعات بسیار کمی یافت می‌شوند که بحث‌برانگیزتر از فناوری بلاک چین و ارزهای دیجیتال باشند! بلاک چین و ارزهای دیجیتال فناوری‌های نوینی هستند که می‌توانند سبب تغییراتی مهم در بازار اجناس مختلف باشند، و بدین دلیل است که توجه روزافزون و سرمایه‌گذاری فعالان عرصه‌های نفت، گاز طبیعی، فلزات، کشاورزی، نیرو و موسسات انتشار اوراق قرضه را به …

?یک venture capital سوئیسی موفق به جذب ۸۹ میلیون یورو برای سرمایه‌گذاری در بیوتکنولوژی پزشکی شد. ?در خارج از ایران نوع خاصی از شرکت‌های سرمایه گذاری وجود دارند که به آن‌ها venture capital گفته می‌شود. این شرکت‌ها معمولا با سرمایه‌گذاری روی استارتاپ‌ها یا کسب و کارهای جدید در آن‌ها سهیم می‌شوند و سپس با فروش شرکت یا با عرضه‌ی عمومی …

✅طبق مطالعه جدیدی که درجلسه ۲۷ام فوریه در محل کاخ سفید برای تعیین سرنوشت استاندارد سوخت‌های تجدید‌پذیر مورد بررسی قرار گرفت، ابقا ۵۰۰۰۰ شغل در Iowa به تولید سوخت‌های زیستی گره خورده است. تلاش‌های افرادی همچون Texas Sen. Ted Cruz, R-Texasبرای متقاعد کردن کاخ سفید که درصورت تضعیف استاندارد سوخت‌های تجدیدپذیر (RFS)، شغل‌های مرتبط و زندگی هزاران خانواده کشاورزان در …

مرور مقالات پزشکی مولکولی: ?۱. Efficient and cost-effective generation of hepatocyte-like cells through microparticle-mediated delivery of growth factors in a 3D culture of human pluripotent stem cells Journal: Biomaterials Impact Factor: 8.402 ✍ Link ?۲. An innovative paradigm of methods in microRNAs detection: highlighting DNAzymes, the illuminators Journal: Biosensors and Bioelectronics Impact Factor: 7.780 ✍ Link ?۳. Exosomes in Cancer …

?شرکت نام آشنای Merck که اخیرا با تایید FDA به داروی بر پایه checkpoint inhibitor خود، Pembrolizumab (تحت نام تجاری Keytruda) به عنوان شرکتی پیشگام در عرصه‌ی ایمنی‌درمانی سرطان مطرح شده است، قصد دارد با خرید سهام Viralytics کارآزمایی بالینی را که توسط این شرکت برای تلفیق دو داروی Keytruda و Cavatak انجام می‌شود، تحت کنترل خود بگیرد. ?شرکت استرالیایی …

✅تولید پیش‌ماده RNAهای دورشته‌ای برای تنظیم بیان ژن در زمان نمو گیاه و پاسخ به تنش‌ها ضروری است. تولید RNAهای کوچک نیازمند فعالیت گروه متنوعی از عناصر است. اگرچه در اغلب گونه‌های گیاهی منابع جهش‌یافته برای مطالعه هر جزء ناکافی هستند. در این رابطه، تیم پژوهشی ‌شان کرتین از دانشگاه مینه‌سوتا با استفاده از پلتفرم CRISPR-Cas9 و TALENها، نمونه‌های جهش‌یافته …

?لانتوس با فروش ۶.۰۵ میلیارد دلار دهمین داروی پرفروش دنیاست که در سال‌های گذشته جایگاه بالاتری را در این جدول به خود اختصاص داده بود؛ و افت فروش ۱۱ درصدی را تجربه می‌کند. علت این افت را می‌توان اتمام پتنت این دارو در سال ۲۰۱۴ و همچنین وارد شدن داروی‌های رقیبی همچون detemir به بازار دانست. ?این دارو‌ی ساخت شرکت …

NEW YORK (GenomeWeb) – Biodesix said today it has increased the size of its offering of Series G preferred shares in a follow-on sale, and has simultaneously entered a debt refinancing agreement with Innovatus Capital Partners for a $23 million term loan. The company said it plans to use the additional capital to fund development of blood-based tests for guiding …

Celgene has paid $101 million to collaborate with Vividion on the discovery of small molecules that hit hard-to-drug proteins. The four-year alliance tasks Vividion with discovering drugs that interact with the ubiquitin proteasome system cells use to break proteins apart. Vividion broke cover last year with $50 million from ARCH, Versant and Cardinal Partners, technology from Scripps Research Institute and …

Summary Current market capitalization is ~$375m. Ongoing litigation between PDL BioPharma and Wellstat could result in a payment to PDLI of up to $145m. Case is likely to be resolved by end of 2019. The judge already decided in favor of PDLI but had their judgment remanded based on a procedural point. The same judge presides and is likely to …

NEW YORK (GenomeWeb) – The University of Texas at Arlington (UTA) announced this week that it has partnered with the University of North Texas Health Science Center to launch a new center for next-generation sequencing. Slated to open later this month, the North Texas Genome Center (NTGC) will feature five Illumina NovaSeq 6000 systems and offer whole-genome and exome sequencing …

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission today, CareDx reported that it has entered into a $35 million term loan agreement with Perceptive Credit Holdings. The loan will be provided in two tranches, the SEC filing noted. The first tranche of either $15 million or $25 million of debt will be available upon …

This story has been updated from a previous version to include information about BioCartis’ new US R&D center. NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis today reported that its full-year 2017 revenues rose 74 percent year over year, driven by a 91 percent jump in total product sales revenues. For the 12 months ended Dec. 31, Biocartis’ total …

This story has been updated from a previous version to include information about BioCartis’ new US R&D center. NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis today reported that its full-year 2017 revenues rose 74 percent year over year, driven by a 91 percent jump in total product sales revenues. For the 12 months ended Dec. 31, Biocartis’ total …

Adequate paid family and medical leave in the United States is necessary for the health and economic welfare of individuals and families. Adequate paid leave ensures workers are able to tend to a newborn baby with health benefits for both baby and parents, and the positive health dividends continue for years to come. It allows workers to care for seriously …

Rubius Therapeutics said today it has raised $100 million in new financing to further support clinical development and manufacturing of its new red blood cell–derived therapies. The oversubscribed $100 million “crossover” financing brings to more than $220 million the amount of capital raised by the company. In June, Rubius closed on $120 million in a private financing round it said …

NEW YORK (GenomeWeb) – Rosetta Genomics has agreed to a $9 million buyout by Genoptix, marking the companies’ second attempt at a merger. In December, Genoptix signed an agreement to acquire Rosetta for $10 million in cash. The deal came at a key time for Rosetta, which has undergone a series of organizational changes in recent months — including layoffs — and expects to …

Developing sustainable energy sources is a national quest of scientists in both the private industry and public university sector. Among these endeavors is the recently started Sustainable Bio-economy for Arid Regions project led by the University of Arizona. Sangu Angadi, New Mexico State University crop physiologist and associate professor, holds a guar plant at the Agricultural Science Center at Clovis. …

Uganda Investment Authority has entered a multi-billion deal with a Malaysian firm with an aim of transforming the country into a green economy by 2040 through a series of four integrated green projects led by bio-fuels. The $70bn project will be implemented by Bionas East Africa Group Limited, a subsidiary of Bionas Agropolitan Technology Corridor (BATC) Development Berhad. The implementation will …

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it has reached an agreement with Memorial Sloan Kettering Cancer Center to develop and commercialize products and services that include assessment of tumor mutation burden (TMB) biomarker status. Under the terms of the licensing agreement, PGDx receives exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual …

?پس از معرفی سیستم بلاک‌چین در سال ۲۰۰۸ و ایجاد نخستین ارز بر پایه دیجیتال یا بیت‌کوین، این ارز پیشرفت زیادی داشته است به طوری که پیش‌بینی می‌شود در سال ۲۰۲۵، ده درصد تولید ناخالص داخلی جهان بر روی تکنولوژی زنجیره بلوکی ذخیره خواهد‌ شد. اما ارز‌های دیجیتال فقط یکی از موارد کاربرد این تکنولوژی هستند. با استفاده از بلاک‌چین …

Summary The company is brewing a specialized pipeline of therapeutics to potentially capture lucrative food allergy market share. And, lead molecule AR-101 recently posted stellar phase 3 (PALISADE) trial outcomes for peanut allergy. Given the robust data for peanut allergy, the chances of other therapeutics (for walnut and egg) to work increased substantially. Partnership deal with Sanofi/Regeneron to co-develop AR-101 …

Summary BioTime is a complicated company with considerable potential hampered by a too vast platform. After almost three decades, the company is finally nearing the market with its first product. Although there is much to be concerned about, BTX offers an interesting speculative opportunity. In a series of articles, we will take a detailed look at the company. Introduction: of …

By Brent Erickson, executive vice-president; Head, Industrial & Environmental Section, Biotechnology Innovation Organization Special to The Digest This week, I’ll be addressing the Advanced Biofuels Leadership Conference. I’d like to thank Jim Lane for giving me that opportunity again this year. I appreciate it, because BIO is the only trade association that advocates for the diverse policies that support the …

Summary Clovis Oncology has a number of regulatory catalysts that can drive share price higher. Scientific Advisory issued a positive opinion on approval in Europe to the CHMP. Strong data from ARIEL3 favors approval in April FDA PDUFA. Share price weakness is a good entry point ahead of upcoming catalysts. Clovis Oncology, Inc. (CLVS) is a biopharmaceutical company with lead …

Summary We seem to be trading in a narrow range this week with a break possible in either direction. Why did Gilead sign a multibillion-dollar deal for zinc finger genomic editing technology and not CRISPR/Cas9? We discuss some possible reasons why Gilead may have opted for Zinc finger technology. We seem to be trading in a narrow range this week …

Summary AbbVie announced that elagolix met its primary and secondary efficacy endpoints in the first of two Phase III studies for uterine fibroids. Uterine fibroids is another potential multibillion-dollar indication for AbbVie and Neurocrine given the large, underserved patient population and the combination of elagolix’s efficacy and safety. This clinical success pushes my fair value to $95 and there could …

Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials. Sydney-based Viralytics’ most advanced candidate is Cavatak, a common cold RNA virus. Viralytics selected the nongenetically altered virus on the strength of its ability to target ICAM-1 and infect a variety …